ALSUntangled #64: butyrates

Yuyao Sun; Richard Bedlack; Carmel Armon; Morgan Beauchamp; Tulio Bertorini; Robert Bowser; Mark Bromberg; James Caress; Gregory Carter; Jesse Crayle; Merit E. Cudkowicz; Jonathan D. Glass; Carlayne Jackson; Isaac Lund; Sarah Martin; Sabrina Paganoni; Gary Pattee; Dylan Ratner; Kristiana Salmon; Paul Wicks

doi:10.1080/21678421.2022.2045323

ALSUntangled #64: butyrates

Yuyao Sun, Richard Bedlack, Carmel Armon, Morgan Beauchamp, Tulio Bertorini, Robert Bowser, Mark Bromberg, James Caress, Gregory Carter, Jesse Crayle, Merit E. Cudkowicz, Jonathan D. Glass, Carlayne Jackson, Isaac Lund, Sarah Martin, Sabrina Paganoni, Gary Pattee, Dylan Ratner, Kristiana Salmon, Paul Wicks

Department of Neurology

Producción científica: Review article › revisión exhaustiva

9 Citas (Scopus)

Resumen

ALSUntangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). Here we review butyrate and its different chemical forms (butyrates). Butyrates have plausible mechanisms for slowing ALS progression and positive pre-clinical studies. One trial suggests that sodium phenylbutyrate (NaPB) in combination with Tauroursodeoxycholic acid (TUDCA) can slow ALS progression and prolong survival, but the specific contribution of NaPB toward this effect is unclear. Butyrates appear reasonably safe for use in humans. Based on the above information, we support a trial of a butyrate in PALS, but we cannot yet recommend one as a treatment.

Idioma original	English (US)
Páginas (desde-hasta)	638-643
Número de páginas	6
Publicación	Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Volumen	23
N.º	7-8
DOI	https://doi.org/10.1080/21678421.2022.2045323
Estado	Published - 2022

ASJC Scopus subject areas

Clinical Neurology
Neurology

Acceder al documento

10.1080/21678421.2022.2045323

Otros archivos y enlaces

Citar esto

Sun, Y., Bedlack, R., Armon, C., Beauchamp, M., Bertorini, T., Bowser, R., Bromberg, M., Caress, J., Carter, G., Crayle, J., Cudkowicz, M. E., Glass, J. D., Jackson, C., Lund, I., Martin, S., Paganoni, S., Pattee, G., Ratner, D., Salmon, K., & Wicks, P. (2022). ALSUntangled #64: butyrates. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 23(7-8), 638-643. https://doi.org/10.1080/21678421.2022.2045323

Sun, Y, Bedlack, R, Armon, C, Beauchamp, M, Bertorini, T, Bowser, R, Bromberg, M, Caress, J, Carter, G, Crayle, J, Cudkowicz, ME, Glass, JD, Jackson, C, Lund, I, Martin, S, Paganoni, S, Pattee, G, Ratner, D, Salmon, K & Wicks, P 2022, 'ALSUntangled #64: butyrates', Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, vol. 23, n.º 7-8, pp. 638-643. https://doi.org/10.1080/21678421.2022.2045323

@article{dd3d1c7edb0441b3b03dc5a7b1f29b1d,

title = "ALSUntangled #64: butyrates",

abstract = "ALSUntangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). Here we review butyrate and its different chemical forms (butyrates). Butyrates have plausible mechanisms for slowing ALS progression and positive pre-clinical studies. One trial suggests that sodium phenylbutyrate (NaPB) in combination with Tauroursodeoxycholic acid (TUDCA) can slow ALS progression and prolong survival, but the specific contribution of NaPB toward this effect is unclear. Butyrates appear reasonably safe for use in humans. Based on the above information, we support a trial of a butyrate in PALS, but we cannot yet recommend one as a treatment.",

keywords = "ALS, alternative therapy, butyrate, gut microbiome, neuroinflammation",

author = "Yuyao Sun and Richard Bedlack and Carmel Armon and Morgan Beauchamp and Tulio Bertorini and Robert Bowser and Mark Bromberg and James Caress and Gregory Carter and Jesse Crayle and Cudkowicz, {Merit E.} and Glass, {Jonathan D.} and Carlayne Jackson and Isaac Lund and Sarah Martin and Sabrina Paganoni and Gary Pattee and Dylan Ratner and Kristiana Salmon and Paul Wicks",

note = "Publisher Copyright: {\textcopyright} 2022 World Federation of Neurology on behalf of the Research Group on Motor Neuron Diseases.",

year = "2022",

doi = "10.1080/21678421.2022.2045323",

language = "English (US)",

volume = "23",

pages = "638--643",

journal = "Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration",

issn = "2167-8421",

publisher = "Informa Healthcare",

number = "7-8",

}

TY - JOUR

T1 - ALSUntangled #64

T2 - butyrates

AU - Sun, Yuyao

AU - Bedlack, Richard

AU - Armon, Carmel

AU - Beauchamp, Morgan

AU - Bertorini, Tulio

AU - Bowser, Robert

AU - Bromberg, Mark

AU - Caress, James

AU - Carter, Gregory

AU - Crayle, Jesse

AU - Cudkowicz, Merit E.

AU - Glass, Jonathan D.

AU - Jackson, Carlayne

AU - Lund, Isaac

AU - Martin, Sarah

AU - Paganoni, Sabrina

AU - Pattee, Gary

AU - Ratner, Dylan

AU - Salmon, Kristiana

AU - Wicks, Paul

PY - 2022

Y1 - 2022

N2 - ALSUntangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). Here we review butyrate and its different chemical forms (butyrates). Butyrates have plausible mechanisms for slowing ALS progression and positive pre-clinical studies. One trial suggests that sodium phenylbutyrate (NaPB) in combination with Tauroursodeoxycholic acid (TUDCA) can slow ALS progression and prolong survival, but the specific contribution of NaPB toward this effect is unclear. Butyrates appear reasonably safe for use in humans. Based on the above information, we support a trial of a butyrate in PALS, but we cannot yet recommend one as a treatment.

AB - ALSUntangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). Here we review butyrate and its different chemical forms (butyrates). Butyrates have plausible mechanisms for slowing ALS progression and positive pre-clinical studies. One trial suggests that sodium phenylbutyrate (NaPB) in combination with Tauroursodeoxycholic acid (TUDCA) can slow ALS progression and prolong survival, but the specific contribution of NaPB toward this effect is unclear. Butyrates appear reasonably safe for use in humans. Based on the above information, we support a trial of a butyrate in PALS, but we cannot yet recommend one as a treatment.

KW - ALS

KW - alternative therapy

KW - butyrate

KW - gut microbiome

KW - neuroinflammation

UR - http://www.scopus.com/inward/record.url?scp=85125936287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85125936287&partnerID=8YFLogxK

U2 - 10.1080/21678421.2022.2045323

DO - 10.1080/21678421.2022.2045323

M3 - Review article

C2 - 35225121

AN - SCOPUS:85125936287

SN - 2167-8421

VL - 23

SP - 638

EP - 643

JO - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

JF - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

IS - 7-8

ER -

ALSUntangled #64: butyrates

Resumen

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto